Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Francesco Cellini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2145-2300; OpenAlex author ID A5074512572. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 4 papers · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 22

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Conventionally Fractionated Radiotherapy (CFRT) Versus Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer: A Systematic Review and Me… Co-author DOI 10.3390/cancers18060971↗
  3. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PA… Co-author DOI 10.3390/curroncol30060427↗
  4. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. Co-author DOI 10.1159/000525945↗
  5. The impact of radiomics in diagnosis and staging of pancreatic cancer. Co-author DOI 10.1177/26317745221081596↗
  6. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review. Co-author DOI 10.3390/curroncol29040214↗
  7. Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm? Co-author DOI 10.3390/life12040465↗
  8. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03411-7↗
  9. Correction to: Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Co-author DOI 10.1007/s00432-020-03439-9↗
  10. Definition of Local Recurrence Site in Resected Pancreatic Adenocarcinoma: A Multicenter Study (DOLORES-1). Co-author DOI 10.3390/cancers13123051↗
  11. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Co-author DOI 10.1002/cam4.3330↗
  12. On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations. Co-author DOI 10.1016/j.tipsro.2020.06.001↗
  13. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Co-author DOI 10.21873/anticanres.13975↗
  14. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical … Co-author DOI 10.3390/cancers12071729↗
  15. Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer. Co-author DOI 10.1002/acm2.12697↗
  16. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  17. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a m… First author DOI 10.1080/0284186x.2018.1546899↗
  18. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. First author DOI 10.1186/s12885-019-5790-2↗
  19. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Co-author DOI 10.1186/s13014-019-1275-3↗
  20. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. Co-author DOI 10.2147/jpr.s167994↗
  21. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  22. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessio Giuseppe Morganti · 15 shared papers, 2016–2023 · strength 1.39
  2. Vincenzo Valentini · 14 shared papers, 2016–2022 · strength 1.37
  3. Gian Carlo Mattiucci · 12 shared papers, 2019–2023 · strength 1.24
  4. Gabriella Macchia · 12 shared papers, 2018–2023 · strength 1.19
  5. Milly Buwenge · 11 shared papers, 2018–2023 · strength 1.10
  6. Nicola Simoni · 7 shared papers, 2019–2026 · strength 0.87
  7. Alessandra Arcelli · 9 shared papers, 2018–2023 · strength 0.86
  8. Luca Boldrini · 6 shared papers, 2019–2022 · strength 0.69
  9. Savino Cilla · 6 shared papers, 2019–2023 · strength 0.61
  10. Michele Fiore · 4 shared papers, 2020–2026 · strength 0.56
  11. Renzo Mazzarotto · 5 shared papers, 2020–2023 · strength 0.56
  12. Domenico Genovesi · 4 shared papers, 2019–2026 · strength 0.51
  13. S. Cammelli · 5 shared papers, 2018–2022 · strength 0.48
  14. Davide Cusumano · 4 shared papers, 2019–2022 · strength 0.45
  15. Nunziata D’Abbiero · 2 shared papers, 2022–2026 · strength 0.40
  16. Lidia Strigari · 3 shared papers, 2021–2023 · strength 0.38
  17. Mariacristina Di Marco · 4 shared papers, 2019–2023 · strength 0.37
  18. Sergio Alfieri · 3 shared papers, 2019–2022 · strength 0.26
  19. Luca Nicosia · 1 shared paper, 2026 · strength 0.24
  20. Marcin Miszczyk · 1 shared paper, 2026 · strength 0.24
  21. Francesca De Felice · 1 shared paper, 2026 · strength 0.24
  22. Giampaolo Montesi · 1 shared paper, 2026 · strength 0.24
  23. Massimo Falconi · 4 shared papers, 2016–2019 · strength 0.24
  24. Michele Reni · 4 shared papers, 2016–2019 · strength 0.24
  25. Riccardo Casadei · 3 shared papers, 2019–2020 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.